With multi-national pharmaceutical companies (MNCs) looking more and more into large emerging markets as a promising source of growth, how important is Mexico in Roche’s expansion plans?
It is crucial. Roche has for some time been focusing its attention on the E7 countries as a key source of growth. We have a unique portfolio that we have already launched very successfully in developed markets and, given that the population pyramid is changing in the E7 countries, this portfolio will soon be an excellent match for these markets. It is already suitable for Mexico but it will also be for several other countries in the near future. That is why it is common sense for a global leader as Roche to keep a strong presence and invest in the E7 markets as they will be the main source of growth for the whole pharmaceutical industry. You had the opportunity of working in different markets. Do you consider that MNCs should apply the same exact model that has allowed them to succeed in the developed world in the E7 countries? If you look at European markets, they all behave in a pretty similar manner. On the contrary, if you compare Mexico with Brazil, or Mexico with Russia, you will
